Molecular structure of LY500307, CAS Number: 533884-09-2
LY500307 (CAS 533884-09-2)
Alternate Names:
Erteberel
Application:
LY500307 is a potent activator to both ERα and ERβ
CAS Number:
533884-09-2
Purity:
≥95%
Molecular Weight:
282.33
Molecular Formula:
C18H18O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
LY500307 potently binds both ERα (Ki 2.68 nM) and ERβ (Ki 0.19 nM). LY500307 shows full agonist function in both ERα and ERβ assays (>90% relative efficacy) and displays potent inhibition toward ERβ with EC50 of 0.66 nM.
LY500307 (CAS 533884-09-2) References
- Fertility and developmental toxicity assessment in rats and rabbits with LY500307, a selective estrogen receptor beta (ERβ) agonist. | Hilbish, KG., et al. 2013. Birth Defects Res B Dev Reprod Toxicol. 98: 400-15. PMID: 24323950
- Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy. | Roehrborn, CG., et al. 2015. Prostate Cancer Prostatic Dis. 18: 43-8. PMID: 25348255
- Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. | Sareddy, GR., et al. 2016. Sci Rep. 6: 24185. PMID: 27126081
- ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer. | Reese, JM., et al. 2017. Oncotarget. 8: 96506-96521. PMID: 29228549
- Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis. | Zhao, L., et al. 2018. Proc Natl Acad Sci U S A. 115: E3673-E3681. PMID: 29592953
- Activation of estrogen receptor beta signaling reduces stemness of glioma stem cells. | Sareddy, GR., et al. 2021. Stem Cells. 39: 536-550. PMID: 33470499
- Mitochondrial estrogen receptors alter mitochondrial priming and response to endocrine therapy in breast cancer cells. | Karakas, B., et al. 2021. Cell Death Discov. 7: 189. PMID: 34294688
- Drivers and suppressors of triple-negative breast cancer. | Wu, W., et al. 2021. Proc Natl Acad Sci U S A. 118: PMID: 34389675
- Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma. | Pratap, UP., et al. 2021. Neurooncol Adv. 3: vdab099. PMID: 34485908
- Different Susceptibilities of Human Melanoma Cell Lines to G2/M Blockage and Cell Death Activation in Response to the Estrogen Receptor β agonist LY500307. | Pontecorvi, G., et al. 2022. J Cancer. 13: 1573-1587. PMID: 35371312
- Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer. | Datta, J., et al. 2022. Front Oncol. 12: 857590. PMID: 35574319
- Ahi1 regulates serotonin production by the GR/ERβ/TPH2 pathway involving sexual differences in depressive behaviors. | Wang, B., et al. 2022. Cell Commun Signal. 20: 74. PMID: 35643536
- Therapeutic Targeting of Ovarian Cancer Stem Cells Using Estrogen Receptor Beta Agonist. | He, Y., et al. 2022. Int J Mol Sci. 23: PMID: 35806169
Inhibitor of:
ER beta.Activator of:
ER alpha, and ER beta.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LY500307, 5 mg | sc-364530 | 5 mg | $600.00 | |||
LY500307, 25 mg | sc-364530A | 25 mg | $1600.00 | |||
LY500307, 100 mg | sc-364530B | 100 mg | $6000.00 | |||
LY500307, 200 mg | sc-364530C | 200 mg | $11223.00 |